(Reuters) -British pharmaceutical giant GlaxoSmithKline (NYSE:GSK) and rival Pfizer (NYSE:PFE) have agreed to end a lawsuit that alleged Pfizer’s respiratory syncytial virus (RSV) vaccine ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk ...

Wave Life Sciences Ltd . (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, has been making significant ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Ex-Intel head says TSMC’s new investment will not resurrect US chip sector Read the Market Summary Here:- Highlighted with 142 tables and 105 figures, this 228-page report ?Global Pharmaceutical ...

Segmentation Analysis Highlighted with 90 tables and 92 figures, this 179-page report represents a 360-degree view on the global market with extensively detailed segmentations by Offering, Application ...

Investing.com -- Shares of Cytokinetics (NASDAQ: NASDAQ:CYTK) climbed 11% after Edgewise Therapeutics reported results for its treatment of hypertrophic cardiomyopathy (HCM), which led to a 28% ...

Investing.com-- The new U.S. tariffs under a second Donald Trump administration could create ripple effects across the technology sector, with e-commerce software vendors among the "most exposed", ...